Mirador Therapeutics has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a potentially long-acting, sweeping anti-C5a antibody designed to inhibit C5a/C5aR-mediated inflammation.  

The agreement expands Mirador’s precision immunology portfolio into inflammatory vascular disease. Kira will receive $12 million upon signing. 

The C5a/C5aR axis is clinically and commercially validated in ANCA-associated vasculitis (AAV), a serious autoimmune condition characterised by inflammation and destruction of small blood vessels.  

While C5aR inhibition has demonstrated meaningful clinical benefit and commercial adoption in AAV, there remains a need for effective next-generation therapies with a favourable safety and tolerability profile. 

“Our strategy is disciplined: We take on big problems in I&I and pair each programme with the modality most likely to succeed for patients. KP-301 is a textbook example of that thesis,” said Mark McKenna, Chairman and CEO of Mirador. “The biology of complement-driven vascular inflammation is well established, yet significant unmet need remains. KP-301 gives us the opportunity to deliver the benefit of C5a signalling inhibition through a differentiated, long-acting antibody, and it expands our portfolio into inflammatory vascular disease, where the science, the modality and the unmet need clearly align.” 

KP-301 is engineered as a long-acting, potent and selective C5a blocker that incorporates next-generation pH-dependent target binding and antibody recycling to overcome target burden that would otherwise limit the dosing interval. This “sweeping” mechanism is intended to enable sustained C5a signaling inhibition at low, infrequent dosing suited to chronic treatment. 

Mirador plans to initiate a Phase I study of KP-301 by year-end 2026 and a Phase II AAV study in the first half of 2027, and to pursue monotherapy and combination expansion into additional inflammatory disease indications.